Apcintex Limited
- Address
- 3rd Floor, 1 Ashley Road
Sponsor Overview
Specializations
Hemophilia B with Inhibitors
Clinical research in hemophilia B with factor inhibitors, centered on bleeding prevention and treatment options for patients whose coagulation management is complicated by antibody development.
- Bleeding prophylaxis
- Inhibitor-associated hemophilia
- Coagulation disorder management
The sponsor’s research activity in this area reflects a focus on patients with limited therapeutic options in rare blood disorders.
Severe Hemophilia A
Clinical interest in severe hemophilia A, with emphasis on reducing spontaneous bleeding episodes and supporting long-term control of a hereditary clotting factor deficiency.
- Factor VIII deficiency
- Spontaneous bleeding prevention
- Inherited bleeding disorders
This area aligns with the sponsor’s involvement in rare hematologic disease research across multiple international sites.
Moderately Severe to Severe Hemophilia B
Research activity focused on moderately severe to severe hemophilia B, addressing recurrent bleeding risk and the need for sustained control in patients with significant factor IX deficiency.
- Factor IX deficiency
- Recurrent hemorrhage prevention
- Long-term bleeding control
The sponsor is active in clinical development for hemophilia populations requiring ongoing prophylactic care.
Rare Bleeding Disorders
The sponsor’s clinical portfolio is concentrated in rare bleeding disorders, with a strong therapeutic emphasis on inherited coagulopathies and the prevention of bleeding complications.
- Inherited coagulopathy
- Bleeding prevention
- Hematology
Its research footprint spans multinational trial activity and collaboration with specialized hematology sites.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Global, Open-label Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Hemophilia B With Inhibitors (PRESent-3) |  France Germany Italy Spain | Not Recruiting |
| A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B (PRESent-2) |  Belgium Bulgaria France Germany Italy Poland Spain | Not Recruiting |
Data & Insights
This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 22 sites across their trial portfolio.
Therapeutic Focus
- 1.Hemic and Lymphatic Diseases2 trials249 other sponsors
Partnered Research Centres
22 centres- Address
- 78 Rue Du General Leclerc, 94270 Le Kremlin-Bicetre
- Address
- 149 Rue De Sevres, 75015 Paris
- Address
- Via Cherasco 15, 10126 Turin
- Address
- Largo Giovanni Alessandro Brambilla 3, 50134 Florence
- Address
- Via Pozzuolo 330, 33100 Udine
- Address
- Rue Michel Polonovski, 59037 Lille
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Apcintex Limited.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.